Industrial Policy & Trade Monitor· 2662 actions· ✨ 89 recent

On 23 May 2026 President Javier Milei, Economy Minister Luis Caputo, and Chief of Staff Manuel Adorni announced the "Régimen de Incentivo para Grandes Inversiones en Nuevas Industrias" (Super RIGI), and on 26 May 2026 submitted the bill (Mensaje 181/2026, expediente 0005-PE-2026) to the Cámara de Diputados — pending Congressional approval as of filing. The regime applies a US$1 billion minimum investment threshold (with ≥20% committed in the first two years), a 15% corporate income tax rate (vs 25% under the base 2024 RIGI), accelerated depreciation of 60%/20%/20% over three years, immediate export-duty exemption (vs year 3 under RIGI), import-tariff exemption, and 30-year regulatory stability across tax, customs, social security, and FX matters. A progressive FX-liberalisation schedule allows 20% / 40% / 100% free disposal of export-generated foreign currency in years 1 / 2 / 3+. Target sectors are industries that "do not currently exist or are in experimental/pilot phase in Argentina," including semiconductors, AI data centres, advanced biotech, 100% electric vehicles, lithium value chain (downstream processing, cathode, battery), green hydrogen, solar panels, wind turbines, onshore LNG, SMR nuclear, aerospace, uranium value chain, potassium and phosphorus fertilisers, and new petrochemicals.

The Decreto para la Autorización Inmediata de Inversiones, published in Mexico's Diario Oficial de la Federación on 4 May 2026, creates a streamlined investment-authorization mechanism under President Sheinbaum's Plan México strategy. The decree establishes an Investment Committee — composed of the Secretariats of Economía, Hacienda, SEMARNAT, SCT, Energía, and Bienestar — mandated to issue authorization certificates within 30 business days for qualifying projects, replacing the historic 6–18-month multi-agency backlog. Eligibility covers three tiers: projects in designated Polos de Desarrollo Económico para el Bienestar (Welfare Development Poles), investments of MXN 2 billion (≈USD 100M) or more, and projects in strategic sectors (semiconductors, EV batteries, critical minerals, automotive supply chain, medical devices, biotech, aerospace). This is the procedural- acceleration arm of Plan México, structurally distinct from the January 2025 Plan México tax-incentive decree (the fiscal arm), and operationalises the February 2026 Plan México expansion announced by Sheinbaum.

South Korea's 13th National Strategic Technology Special Committee (chaired by MSIT) adopted the 2026 Annual Implementation Plan for the First Basic Plan for National Strategic Technology Development (2024–2028), committing KRW 8.6 trillion in 2026 R&D investment — a ~30% YoY increase from KRW 6.5 trillion in 2025 — across 19 NEXT strategic-technology fields encompassing AI, semiconductors, quantum, displays, and secondary batteries, coordinated across 23 ministries. The plan is supplemented by KRW 46.6 trillion in policy finance delivered through Korea Development Bank (KDB), Industrial Bank of Korea (IBK), Korea Credit Guarantee Fund (KCGF), and Korea Technology Finance Corporation (KOTEC), providing the horizontal funding-coordination architecture that operationalises all sector-specific Korean strategic-technology legislative instruments.

Gujarat Chief Minister Bhupendra Patel launched the Gujarat Science, Technology and Innovation (STI) Policy 2026–2031 on 1 March 2026 at the SemiConnect 2026 Conference in Gandhinagar, establishing a five-year ₹1,000 crore Swadeshi Anusandhan Fund (Indigenous Innovation Fund) for domestic R&D across strategic sectors including AI, semiconductors, quantum technologies, biotechnology, green energy, and defence. The policy targets state STI expenditure of 1% of GSDP by 2030, creation of 1 lakh skilled research professionals, 1,000+ IP filings annually, and builds three Gujarat Rajya Research and Innovation Cluster (GRRIC) corridors to anchor the state's growing semiconductor manufacturing ecosystem.

Uruguay's Poder Ejecutivo promulgated Decreto Nº 329/025 on 23 December 2025, comprehensively overhauling the general investment-promotion framework established under Ley Nº 16.906 (1998) and replacing Decreto 268/020. Administered by COMAP under the Ministerio de Economía y Finanzas, the decree entered into force on 1 February 2026 with a coexistence transition period through 30 April 2026 and became the sole operative instrument from 1 May 2026. The decree extends project timelines, creates tiered investment categories (including a mega-investment tier providing up to 25-year IRAE exemptions), expands incentives for SMEs, and explicitly calibrates the scoring matrix toward decentralisation, innovation, export capacity, and strategic sectors including data-centers, green hydrogen, sustainable forestry-pulp, agtech, and global business services.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

Singapore's National Research Foundation (NRF), under the Prime Minister's Office, launched the five-year Research, Innovation and Enterprise 2030 Plan on 5 December 2025, allocating S$37 billion (approximately 1% of GDP) for 2026-2030. The plan succeeds RIE2025 (S$25 billion) and introduces two named RIE Flagships and two RIE Grand Challenges; the first Flagship is in semiconductors and is explicitly aimed at making Singapore a strategically important R&D and manufacturing node in the global semiconductor supply chain. The budget envelope is split 24% foundational research, 20% innovation and enterprise, 17% infrastructure / new programmes ("white space"), 10% talent development.

The Chongqing Municipal People's Government General Office issued "Several Measures for Chongqing's Full-Chain Support of High-Quality Innovative Drug Development" (Yu Fu Ban Fa [2025] No. 56) on 2025-11-01, a 25-point package of regulatory-fast-track and procurement-support measures for the municipal biopharma sector. It targets 1-3 newly approved innovative drugs per year through 2027 (10 total) and the cultivation of 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters. No direct subsidy or tax-incentive amount is disclosed in the published text — the package is operational (compressed clinical-trial and registration timelines, guaranteed hospital procurement) rather than a cash grant.

On 28 October 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) signed five localization and knowledge-transfer agreements on the sidelines of the Global Health Exhibition 2025, covering domestic manufacture and technology transfer for the biologic drugs etanercept and adalimumab (both used to treat chronic inflammatory / autoimmune conditions) and for orthopedic trauma implants. The adalimumab agreement was signed separately with Boston Oncology Arabia and Tabuk Pharmaceuticals. Boston Oncology's own disclosure of its adalimumab/ etanercept agreement (announced 4 November 2025) put the combined economic impact at over SAR 1.2 billion in cumulative GDP contribution and approximately 500 direct jobs, with production sited at its Sudair Industrial City facility (USFDA/EMA/SFDA-standard). Global Trade Alert's tracking of the same state act records seven counterparties in total (Boston Oncology, Tabuk Pharmaceuticals, Rameem Medical, Bio Vision, Sudair Pharma, Almana Company, and an additional pharma manufacturer), consistent with LCGPA's practice of bundling several related product-localization signings into one event.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

Banque des Territoires, acting on behalf of the French State under the France 2030 programme, launched a EUR 500 million fund-of-funds called "Global Tech Coté" on 7 August 2025. The vehicle takes minority stakes (EUR 15 million minimum, capped at 10% of a target fund's subscribed capital) in privately-managed investment funds that in turn back publicly-listed French technology companies with strong growth potential, aiming to build up domestic asset-management capacity alongside the state's stated goal of channelling capital into equities. The selection window for management companies runs until 31 December 2026 or until the EUR 500 million envelope is exhausted, whichever comes first.

On 1 July 2025 India's Union Cabinet approved the Research Development and Innovation (RDI) Scheme, a six-year, ₹1,00,000 crore (≈USD 11.68 bn) fund to catalyse private-sector investment in research, development and innovation, with ₹20,000 crore allocated for FY2025-26. The scheme finances transformative RDI projects (TRL 4 and above) in strategic and sunrise sectors — deep tech, AI, biotechnology, quantum computing, robotics, space, energy transition and the digital economy — through long-tenor, low-or-nil-interest loans and equity, up to 50% of assessed project cost. Grants and short-term loans are explicitly excluded. Funds flow through a Special Purpose Fund under ANRF (first-level) to second-level fund managers — Alternate Investment Funds, Development Finance Institutions, NBFCs, and focused research bodies including the Technology Development Board (TDB) and BIRAC — which began issuing project calls in February 2026.

Vietnam's government issued Decree No. 160/2025/ND-CP establishing the National Data Development Fund, a non-budget state financial fund capitalised at VND 1 trillion (approx. USD 38.3 million). The fund, administered by the Ministry of Public Security, provides subsidised loans, interest-payment support, and grants — delegated through state-owned commercial and policy banks — to develop and protect data infrastructure and to support AI, big data, cloud computing, blockchain, and IoT projects serving state management and digital-transformation goals, with priority for rural and disadvantaged regions. The decree took effect 1 July 2025.

President Trump signed Executive Order 14273, "Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients", on 12 May 2025. The EO directs HHS, USTR, and Commerce to pursue mechanisms (negotiation targets, importation pathways, and trade-policy levers) to bring the prices Americans pay for innovative prescription drugs into alignment with the *lowest* prices paid by other comparably-developed nations — the "most-favored-nation" (MFN) benchmark. Unlike the Biden-era Inflation Reduction Act drug-price-negotiation provisions (which apply to a handful of Medicare Part D drugs), the EO applies pressure across the broader pharmaceutical pricing surface. As of April 2026, 17 major pharmaceutical manufacturers (incl. Eli Lilly, Pfizer, Bristol-Myers Squibb, AbbVie, Merck, AstraZeneca, Regeneron) have signed bilateral agreements bringing US drug prices toward the international- benchmark level for selected medications.

On 30 April 2025 the General Office of the Guangdong Provincial People's Government issued Yue Fu Ban [2025] No. 11, "Several Measures of Guangdong Province to Further Stimulate Market Entity Vitality and Accelerate the Construction of a Modern Industrial System," effective immediately through 31 December 2027. The package subsidizes bank-loan interest for manufacturing and high-tech enterprises at up to 35% of the loan rate, capped at RMB 2 billion in total annual subsidy volume and RMB 20 million per enterprise per year, alongside an expansion of government-backed financing-guarantee coverage to over RMB 10 billion annually. It also funds foreign-invested R&D centers (up to RMB 1 million, or RMB 5 million for multinational global R&D centers) and offers headquarters-relocation bonuses of up to RMB 8 million, with priority given to semiconductors, AI, robotics, biotechnology, quantum technology, commercial aerospace, and new-energy vehicles.

On 11 March 2025 the European Commission published its proposal for a Critical Medicines Act (CMA), pillar of the broader EU pharmaceutical-resilience agenda alongside the EU Critical Raw Materials Act (filed: 2024-05-23-eu-crma-entry-into-force) and the IRA-style industrial-policy stack. The proposal targets supply security of an EU "Union List" of critical medicines (antibiotics, anti-thrombotics, oncology, cardiovascular, insulin, painkillers) by introducing four mechanisms: (1) Strategic Project status with expedited funding access for critical-medicine manufacturing or active-substance production; (2) public-procurement preferences favouring resilient supply chains and — in defined cases — EU-based production; (3) collaborative cross-Member-State procurement to address fragmented small markets; (4) state-aid framework guidance + international-partnership diversification to reduce single-country (often China-routed) API dependency.

On 19 February 2025 Vietnam's 15th National Assembly adopted Resolution 193/2025/QH15 at its 9th Extraordinary Session, establishing 12 pilot policy categories that operationalise the Politburo's December 2024 Resolution 57-NQ/TW without requiring full-statute enactment. The resolution's most structurally novel element is an R&D risk-acceptance framework — the first in Southeast Asia — that exempts organisations and individuals from civil liability for damage caused to the State in the course of state-funded R&D activities conducted in compliance with prescribed procedures, directly addressing Vietnam's long-standing chilling effect on state-sector innovation. Additional pilots cover expedited procurement for sci-tech and digital-transformation projects, special tax and immigration incentives for high-skilled AI/semiconductor/ quantum R&D personnel, accelerated permitting pathways for priority-sector R&D investments, a start-up grant and venture framework, and an open-data regime for state-held datasets. Implementing Decree 88/2025/ND-CP was issued shortly after adoption; the resolution provides the legal-framework architecture that complements the financial-instrument side (Decree 182/2024/ND-CP, VND 30 trillion Investment Support Fund) and the sectoral-law cluster enacted in late 2025.

The Government of Karnataka, Department of Industries and Commerce, notified the Karnataka Industrial Policy 2025-30 in the Karnataka Gazette on 11 February 2025, with the policy taking legal effect from 8 February 2025 and valid for five years (or until superseded). It supersedes the prior Karnataka Industrial Policy 2020-25. The umbrella state-level framework targets ₹7.5 lakh crore (~USD 90 bn) in fresh investment and 20 lakh (2 million) new jobs by 2030, positioning Karnataka as a top-Asia destination for high-technology manufacturing — semiconductors, EVs, aerospace, defence, biotech, medical devices, textiles and renewable energy. It introduces zone-based incentive categorisation (Zone 1/2/3 district classification), capital subsidies, stamp-duty exemption, electricity-tax exemption, interest subsidy, ESDM-specific top-up incentives that layer onto central PLI/ECMS/Semicon Mission schemes, and a Cabinet Sub-Committee under the Chief Minister to sanction bespoke "Anchor Investor" and "Mega/Ultra-Mega" customised incentive packages.

On 22 December 2024 the Politburo of the Communist Party of Vietnam, under General Secretary Tô Lâm, issued Resolution 57-NQ/TW designating science, technology, innovation, and national digital transformation as Vietnam's "top strategic breakthrough" through 2030 with vision to 2045. The resolution targets ≥50% digital-economy share of GDP, top-30 global ranking in innovation and digital transformation, and at least 10 globally-competitive Vietnamese digital-technology enterprises by 2030. It identifies data, AI, blockchain, and IoT as priority bottlenecks and operates as the parent/umbrella authority under which all subsequent Government, National Assembly, Prime-Ministerial and Ministerial tech-industrial instruments are formulated. Operational implementation runs through Government Resolution 03/NQ-CP of 9 January 2025 (action programme).

Vietnam's 15th National Assembly passed Law 44/2024/QH15 on 21 November 2024, comprehensively amending the 2016 Law on Pharmacy. The law liberalises foreign-invested enterprise (FIE) rights — permitting FIEs to wholesale self-imported drugs and APIs and to operate pharmacy chains for the first time — while introducing a special investment-incentive tier for pharma projects capitalised at ≥ VND 3,000 billion (≈ USD 120m) with ≥ VND 1,000 billion disbursed within three years. Online retail of non-prescription drugs is formally legalised as a distinct regulated business activity. Most provisions take effect 1 July 2025; selected marketing-authorisation renewal procedures took effect 1 January 2025. Implementing Decree 163/2025/ND-CP, effective 1 July 2025, provides detailed operational guidance.

On 26 July 2024 President Erdoğan unveiled the HIT-30 (High-Technology Investment Programme), Türkiye's largest single industrial-finance instrument since the 2018 Investment Office reform, allocating USD 30 billion in state support over 2024-2030 to attract investment across 37 priority programmes spanning electric vehicles, batteries, semiconductors, solar/wind energy, green hydrogen, hyperscale data centres, biotechnological medicine, industrial robotics, and R&D. The Ministry of Industry and Technology is the operating agency, with the Industrialization Executive Committee chaired by the President providing high-level oversight; an Industrialisation Executive Committee under the President directs sectoral allocations. Headline tools include USD 4.5bn earmarked for an 80 GWh battery-manufacturing capacity (with USD 6,000/MWh grants through 2030), USD 2.5bn for 15 GW of domestic solar-cell capacity, USD 1.7bn for wind-component manufacturing, USD 1bn for top-1000 corporate R&D centre support (covering 50% of personnel costs for 5 years), corporate tax reductions, social-security-contribution coverage, energy-cost subsidies covering 50% of bills for energy-intensive projects, customs/VAT exemptions, and free or discounted land allocation in organised industrial zones. Programme targets at least USD 20bn in private-sector co-investment.

On 26 February 2024, President Ferdinand Marcos Jr. signed Republic Act No. 11981 ("Tatak Pinoy Act"), the first standalone national industrial policy law in Philippine history. It mandates the formulation, funding, implementation, monitoring, and evaluation of a multi-year Tatak Pinoy Strategy organised around five pillars (human resources, infrastructure, technology and innovation, investments, sound financial management) and establishes the Tatak Pinoy Council, chaired by the DTI Secretary with NEDA and Finance secretaries as vice-chairs. On 24 October 2025, Marcos issued Memorandum Circular No. 104 approving the implementing Tatak Pinoy Strategy and directing all national agencies, GOCCs, and LGUs to prioritise local products in procurement, with local suppliers eligible for award if their bids are within 25% of the lowest foreign offer.

On 8 December 2022 the Thai Board of Investment issued Announcement No. 8/2565 "Policies and Criteria for Investment Promotion", setting Thailand's five-year (2023-2027) horizontal investment-promotion strategy. The Announcement entered into force from 8:30 a.m. on 3 January 2023 and applies to all investment-promotion applications filed with the BOI from that date. The strategy reorients Thailand's investment regime around three core concepts — (i) innovation, technology and creativity, (ii) competitiveness and rapid adaptability, and (iii) inclusiveness, including environmental and social sustainability — and is operationalised through seven pillars: industrial transition to BCG (Bio-Circular-Green) / smart industries, regional-hub positioning (EV, electronics, food, medical, aviation, automation), supply-chain strengthening, technology upgrading, SME competitiveness, sustainable development, and BCG-economy alignment. Incentives are structured into Group A (corporate-income-tax exemption for 3-13 years, with Group A1+ activities — frontier-technology semiconductors, advanced biotech, certain EV components — receiving up to 10-13 years CIT exemption with no cap) and Group B (non-tax incentives only). Fundamental eligibility criteria carried over from prior regimes: minimum THB 1 million investment, new-machinery requirement, 20% annual revenue-growth projection, and a 3:1 debt-to-equity threshold. The 8 December 2022 release was accompanied by 16 additional implementing announcements (Announcements 9/2565 to 24/2565) covering specific activity lists and merit-based incentives. This is the umbrella framework under which Thailand's subsequent sector-specific BOI instruments operate — the EV 3.5 package (2023-12-19, effective 2024-01-01), the EV Board HEV manufacturing excise incentives (2024-07-26), and the National Semiconductor and Advanced Electronics Industry Strategy (2026-01-07) all sit inside this 2023-2027 investment-promotion regime.

France 2030 is a €54 billion public investment plan unveiled by President Emmanuel Macron on 12 October 2021 to fund breakthrough innovation and reindustrialisation across ten strategic priorities — small modular nuclear reactors, green hydrogen, low-carbon transport (incl. two million EVs/year), food/agritech, twenty drug therapies for cancer and chronic disease, cultural industries, space, deep-sea exploration, semiconductors and electronic components, and robotics/digital (AI/cloud). Two cross-cutting rules require 50% of investment to flow to decarbonisation and 50% to emerging innovative players. Operationalised from the 2022 budget law, the plan is coordinated by the Secrétariat général pour l'investissement (SGPI) under the Prime Minister and delivered by ANR, ADEME, Bpifrance and Caisse des Dépôts / Banque des Territoires.